Altimmune, Inc.
Index- P/E- EPS (ttm)-2.41 Insider Own0.80% Shs Outstand43.97M Perf Week10.38%
Market Cap520.88M Forward P/E- EPS next Y-2.27 Insider Trans-19.85% Shs Float40.86M Perf Month131.23%
Income-101.70M PEG- EPS next Q-0.47 Inst Own78.50% Short Float9.65% Perf Quarter93.39%
Sales3.60M P/S144.69 EPS this Y-22.90% Inst Trans3.58% Short Ratio3.09 Perf Half Y34.02%
Book/sh4.20 P/B2.79 EPS next Y-9.80% ROA-44.30% Target Price23.14 Perf Year18.78%
Cash/sh- P/C- EPS next 5Y- ROE-48.70% 52W Range3.83 - 17.26 Perf YTD27.73%
Dividend- P/FCF- EPS past 5Y45.70% ROI-48.70% 52W High-34.76% Beta0.64
Dividend %- Quick Ratio10.00 Sales past 5Y6.40% Gross Margin- 52W Low193.99% ATR0.99
Employees47 Current Ratio10.00 Sales Q/Q41.70% Oper. Margin- RSI (14)70.31 Volatility12.67% 13.91%
OptionableYes Debt/Eq0.00 EPS Q/Q-15.70% Profit Margin- Rel Volume1.24 Prev Close11.70
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout- Avg Volume1.28M Price11.26
Recom1.70 SMA2029.48% SMA5079.20% SMA20032.75% Volume1,577,183 Change-3.76%
Dec-29-21Resumed Jefferies Buy $30
Jun-02-21Initiated H.C. Wainwright Buy $35
Feb-11-21Initiated Guggenheim Buy $36
Dec-14-20Initiated Jefferies Buy $25
Nov-12-20Reiterated B. Riley Securities Buy $31 → $28
Sep-25-20Initiated B. Riley FBR Buy $31
Aug-14-20Initiated Evercore ISI Outperform
Jul-31-20Initiated Piper Sandler Overweight $80
Jul-28-20Initiated JMP Securities Mkt Outperform $50
Feb-24-20Resumed ROTH Capital Buy $13
Jul-19-19Initiated ROTH Capital Buy $8.30
Oct-09-17Initiated Piper Jaffray Overweight $6
Jun-17-22 07:30AM  
Jun-08-22 09:55AM  
Jun-03-22 07:30AM  
May-31-22 07:30AM  
May-23-22 09:55AM  
May-20-22 07:30AM  
May-16-22 07:30AM  
May-14-22 09:51AM  
May-12-22 07:00AM  
May-05-22 07:30AM  
Apr-01-22 03:40PM  
Mar-22-22 12:47PM  
Mar-15-22 07:01AM  
Mar-08-22 07:00AM  
Feb-17-22 03:02PM  
Jan-31-22 07:00AM  
Jan-28-22 04:36AM  
Jan-24-22 02:48PM  
Jan-03-22 07:00AM  
Dec-13-21 06:00AM  
Nov-22-21 04:01PM  
Nov-10-21 04:01PM  
Nov-09-21 04:01PM  
Nov-03-21 04:01PM  
Nov-01-21 03:01PM  
Oct-15-21 09:35PM  
Oct-13-21 04:30PM  
Oct-11-21 03:51PM  
Oct-06-21 04:01PM  
Oct-04-21 07:00AM  
Oct-03-21 08:53PM  
Oct-01-21 05:15PM  
Sep-29-21 06:15PM  
Sep-28-21 07:01AM  
Sep-27-21 04:01PM  
Sep-17-21 06:12AM  
Sep-07-21 04:01PM  
Sep-02-21 06:21AM  
Aug-27-21 08:31AM  
Aug-10-21 04:01PM  
Aug-04-21 04:01PM  
Aug-03-21 03:00PM  
Jul-04-21 03:39AM  
Jun-29-21 04:01PM  
Jun-17-21 01:15AM  
Jun-16-21 07:00AM  
May-27-21 07:00AM  
May-26-21 07:00AM  
May-25-21 09:21AM  
May-17-21 07:00AM  
May-11-21 07:00AM  
May-10-21 07:00AM  
May-05-21 03:00PM  
Apr-29-21 07:00AM  
Apr-03-21 03:07AM  
Apr-01-21 07:00AM  
Mar-25-21 11:46AM  
Mar-22-21 07:00AM  
Mar-15-21 07:00AM  
Mar-14-21 05:55AM  
Mar-12-21 01:00AM  
Mar-09-21 09:40AM  
Mar-08-21 04:01PM  
Feb-25-21 11:15PM  
Feb-22-21 04:30PM  
Feb-18-21 10:24AM  
Feb-17-21 07:02AM  
Feb-01-21 10:30AM  
Jan-14-21 11:15PM  
Jan-11-21 11:23PM  
Jan-06-21 11:15PM  
Jan-04-21 09:46PM  
Dec-30-20 08:00AM  
Dec-23-20 04:01PM  
Dec-16-20 03:51PM  
Dec-11-20 07:00AM  
Dec-08-20 08:00AM  
Nov-25-20 07:00AM  
Nov-16-20 07:00AM  
Nov-13-20 05:23AM  
Nov-10-20 01:00AM  
Nov-09-20 04:05PM  
Nov-03-20 08:00AM  
Oct-30-20 02:40PM  
Oct-26-20 06:22AM  
Oct-15-20 07:00AM  
Oct-13-20 04:56AM  
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roberts M ScotChief Scientific OfficerJun 29Option Exercise2.605,46214,20123,162Jun 30 04:05 PM
Roberts M ScotChief Scientific OfficerJun 29Sale12.005,46265,54617,700Jun 30 04:05 PM
Jorkasky DianeDirectorJun 27Option Exercise3.1517,61055,47217,610Jun 28 04:05 PM
Roberts M ScotChief Scientific OfficerJun 27Option Exercise2.1437,35279,75255,052Jun 28 07:00 PM
Roberts M ScotChief Scientific OfficerJun 27Sale12.0037,352448,25417,700Jun 28 07:00 PM
Jorkasky DianeDirectorJun 27Sale11.7517,610206,9440Jun 28 04:05 PM
Schafer KlausDirectorJun 20Option Exercise2.402796709,179Jun 22 04:10 PM
Drutz DavidDirectorJun 15Buy8.001,0008,00020,012Jun 16 09:27 PM
Drutz DavidDirectorMay 24Buy4.501,2005,40019,012May 25 07:00 PM
Harris Matthew ScottChief Medical OfficerFeb 28Option Exercise1.9230,00057,63941,545Mar 02 07:00 PM
Harris Matthew ScottChief Medical OfficerFeb 28Sale7.5230,000225,60011,545Mar 02 07:00 PM
Roberts M ScotChief Scientific OfficerFeb 01Option Exercise0.006,166019,883Feb 03 07:55 PM
Garg Vipin KPresident and CEOFeb 01Option Exercise0.0016,5450300,503Feb 03 07:56 PM
Harris Matthew ScottChief Medical OfficerFeb 01Option Exercise0.006,166013,728Feb 03 07:56 PM
Drutz DavidDirectorJan 25Option Exercise2.407016817,882Jan 26 07:00 PM
Drutz DavidDirectorDec 14Option Exercise2.4013933417,812Dec 15 07:00 PM
Drutz DavidDirectorNov 19Option Exercise2.407016817,673Nov 19 07:00 PM